Back to search results

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Borderline Resectable Pancreatic Ductal Adenocarcinoma · Resectable Pancreatic Adenocarcinoma · Stage I Pancreatic Cancer AJCC v8 · Stage II Pancreatic Cancer AJCC v8 · Stage III Pancreatic Cancer AJCC v8

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

    Contact: Study coordinator (Kathleen M. Coleman) · kathleen.marie.coleman@emory.edu
    Contact: Principal Investigator (Hussein Hamad, MD, MPH)
Study leads

  • Hussein M Hamad, MD, MPH

    Principal Investigator

    Emory University Hospital/Winship Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)